# DR. REDDY'S LABORATORIES LTD (DRREDDY) - COMPREHENSIVE EQUITY ANALYSIS

**Analysis Date:** February 6, 2026
**Data Vintage:** Q3FY26 (Dec 2025), Stock Price as of Feb 5, 2026: â‚¹1,240-1,275

---

## EXECUTIVE SUMMARY

**RECOMMENDATION: BUY (with Caution)** â­â­â­/5

**Rating:** 3-star (HOLD current position, BUY on dips to â‚¹1,180-1,240)

Dr. Reddy's offers a **compelling risk-reward at current levels (â‚¹1,240-1,260)**, but it's NOT a screaming buy due to multiple regulatory/governance headwinds and execution risks.

### Quick Snapshot

| Metric | Value |
|--------|-------|
| **Current Price** | â‚¹1,250 |
| **Market Cap** | â‚¹1,04,000 Cr |
| **P/E** | 18.4x (15% discount to 5Y median) |
| **Intrinsic Value** | â‚¹1,500-1,750 |
| **Upside Potential** | 20-40% (Base to Bull case) |
| **Key Catalyst** | Semaglutide launch (Mar 2026 India, Feb-May Canada) |
| **Key Risk** | â‚¹2,396 Cr tax notice + Regulatory issues |

---

## SECTION 1: BUSINESS OVERVIEW

### 1. Business Model

**Dr. Reddy's Laboratories** is a vertically-integrated global pharmaceutical company founded in 1984, headquartered in Hyderabad.

**Revenue Streams (FY25):**
- **Global Generics**: ~83% of revenues (~â‚¹27,100 Cr)
  - North America: ~40% of generics (dominated by US market)
  - India: ~19% (â‚¹5,992 Cr in 9MFY26)
  - Emerging Markets: ~15% (â‚¹4,960 Cr in 9MFY26)
  - Europe & Others: Balance
  
- **Pharmaceutical Services & Active Ingredients (PSAI)**: ~8-10% (â‚¹2,760 Cr in 9MFY26)
  - APIs, Custom Pharmaceutical Services
  - 150+ APIs manufactured
  
- **Others**: Biosimilars, proprietary products, consumer healthcare

**Geographic Mix (9MFY26):**
- North America: 36%
- India: 23%
- Emerging Markets: 19%
- Europe: 11%
- PSAI: 11%

**Key Therapeutic Areas:**
- Nervous system drugs (14%)
- Gastrointestinal (13%)
- Anti-infectives (10%)
- Cardiovascular, anti-diabetic, dermatology, oncology

---

### 2. Industry Structure

**Market Size:**
- Global generics market: ~$400-450 billion
- Indian pharma market: ~$50 billion, growing to $130 billion by 2030
- GLP-1 market (relevant for semaglutide): ~$30 billion globally

**Growth Rate:**
- Global generics: 5-7% CAGR
- Indian pharma: 9-11% CAGR
- Emerging markets: 8-10% CAGR
- Biosimilars: 15-20% CAGR

**Competitive Intensity:** HIGH
- North America: Intense pricing pressure, consolidated buyers
- India: Highly fragmented (3,000+ companies)
- Emerging Markets: Growing middle class, regulatory complexity varies

---

### 3. Market Position

**Market Share:**
- **India IPM Rank:** #9 (as of Dec 2025)
- **Global Generics:** Top 10 player globally
- **US Market:** Among top 5 Indian pharma companies by US revenues
- **Russia:** Strong #2-3 position

**Key Differentiators:**
1. Vertically integrated (API to formulations)
2. Complex generics expertise (Lenalidomide, biosimilars)
3. 23 manufacturing facilities globally
4. 9 R&D centers with 2,000+ scientists
5. Strong regulatory filing track record (133 DMFs, 400+ ANDAs filed)
6. Semaglutide pipeline - potential first-mover advantage in 87 countries

---

## SECTION 2: MOAT ANALYSIS

| Moat Type | Rating | Evidence |
|-----------|--------|----------|
| **Brand / Pricing Power** | **MODERATE** | Strong in India (#9 IPM rank); Limited in US generics |
| **Switching Costs** | **WEAK** | Generic drugs = low switching costs |
| **Network Effects** | **ABSENT** | No network effects in pharma business model |
| **Cost Advantage / Scale** | **MODERATE** | Vertical integration provides 200-300 bps cost advantage |
| **Regulatory / License Barrier** | **STRONG** | 400+ ANDA approvals, complex ANDAs, biosimilar expertise |
| **Intangible Assets** | **MODERATE** | 133 Drug Master Files, R&D pipeline |

### Overall Moat Rating: **NARROW**

**Rationale:** Strong regulatory/licensing moat and scale advantages, but offset by commoditized generics business, pricing pressure, and moderate switching costs. The moat is sustainable for 5-7 years but requires continuous R&D investment to maintain.

---

## SECTION 3: FINANCIAL ANALYSIS (10-Year View)

### A. Profitability & Returns

| Metric | FY25 (TTM) | FY24 | FY23 | 5Y Avg | 10Y Avg | Trend |
|--------|---------|------|------|--------|---------|-------|
| **ROCE (%)** | 22.7 | 27.0 | 27.2 | 20.4 | 16.0 | â†— â†’ |
| **ROE (%)** | 18.0 | 18.0 | 20.0 | 17.0 | 16.0 | â†’ |
| **Operating Margin (%)** | 25 | 28 | 26 | 23 | 20 | â†’ â†“ |
| **Net Profit Margin (%)** | 17 | 17 | 18 | 12 | 11 | â†— |

**Key Observations:**
- ROCE peaked at 27% in FY23-24; Q3FY26 annualized ROCE of 20.4% shows normalization
- ROE consistently 17-20% - superior to cost of equity
- Margin pressure visible in Q3FY26: OPM 23.5% vs 27-28% in FY24

---

### B. Growth

| Metric | 3Y CAGR | 5Y CAGR | 10Y CAGR | Comment |
|--------|---------|---------|----------|---------|
| **Revenue** | 15% | 13% | 8% | Strong acceleration post-COVID |
| **EBITDA** | 25% | 22% | 12% | Margin expansion + volume growth |
| **PAT** | 38% | 22% | 9% | Exceptional profit growth FY22-25 |
| **EPS** | 36% | 23% | 9% | No dilution |

---

### C. Balance Sheet Strength

| Metric | Q3FY26 | FY25 | Threshold | Status |
|--------|--------|------|-----------|--------|
| **Debt/Equity** | 0.16 | 0.17 | < 0.5 | âœ… **EXCELLENT** |
| **Interest Coverage** | 19.2x | 27.1x | > 5x | âœ… **EXCELLENT** |
| **Current Ratio** | 1.92 | 1.89 | > 1.5 | âœ… **GOOD** |
| **Net Debt/(Cash)** | (â‚¹3,069 Cr) | (â‚¹2,410 Cr) | Negative | âœ… **NET CASH** |

**Assessment:** **FORTRESS BALANCE SHEET** - Net cash position, zero promoter pledge, conservative leverage

---

### D. Cash Flow Quality

| Metric | FY25 | FY24 | 5Y Avg | Comment |
|--------|------|------|--------|---------|
| **CFO (â‚¹ Cr)** | 4,643 | 4,543 | 3,955 | Strong |
| **FCF (â‚¹ Cr)** | 858 | 509 | 1,085 | Q3FY26: â‚¹374 Cr |
| **FCF/PAT (%)** | 15% | 9% | 25% | **CONCERN: Low FCF conversion** |
| **Capex/CFO (%)** | 125% | 89% | 65% | FY25 capex high - biosimilars expansion |

**Red Flags:**
- FCF/PAT collapsed from 39% (FY23) to 15% (FY25) - heavy capex cycle
- FY25 capex of â‚¹5,785 Cr - biosimilars facility at Bachupally

---

### E. Capital Allocation Track Record

**Score:** **AVERAGE to GOOD**

**Dividend Policy:**
- Consistent dividend: â‚¹8/share (FY25), Yield 0.65%
- Payout Ratio: 11-12% - very conservative

**Concerns:**
- Related party transactions: History of buying land/assets from promoter entities
- Write-offs: â‚¹800-1,500 Cr annual impairments on drug acquisitions

---

## SECTION 4: MANAGEMENT & GOVERNANCE

| Factor | Status | Red Flag? |
|--------|--------|-----------|
| **Promoter Holding (%)** | 26.64% (Sep 2025) | âš ï¸ Low for family-run business |
| **Promoter Pledge (%)** | 0% | âœ… **EXCELLENT** |
| **Related Party Transactions** | Regular sales/purchases with group entities | âš ï¸ **WATCH CLOSELY** |
| **Auditor** | S.R. Batliboi & Associates (EY) | âœ… No changes, no qualifications |
| **Litigation / Regulatory** | **â‚¹2,396 Cr tax demand**; Multiple FDA Form 483s | ğŸš¨ **HIGH RISK** |

### Key Management Team
- **K. Satish Reddy:** Executive Chairman
- **G.V. Prasad:** Co-Chairman & MD
- **Erez Israeli:** CEO, North America & Global Generics

### Governance Concerns

**1. Tax Litigation:**
- â‚¹2,396 Cr demand notice (April 2025) on DRHL merger
- Company is contesting; no provision made yet

**2. Regulatory Issues:**
- Dec 2025: Form 483 with 5 observations at Srikakulam facility
- Jan 2026: PAAL for rituximab biosimilar at Bachupally
- Dec 2025: CRL for AVT03 denosumab

### Management Quality Score: **MEDIUM**

### Governance Risk: **MEDIUM-HIGH**

---

## SECTION 5: VALUATION ANALYSIS

### A. Absolute Valuation

| Metric | Current (Feb 2026) | 5Y Median | 10Y Median | Premium/Discount |
|--------|------------|-----------|------------|------------------|
| **P/E** | 18.4 | 22.0 | 21.0 | **-16% discount to 5Y** |
| **EV/EBITDA** | 12.2 | 14.5 | 13.0 | **-16% discount** |
| **P/B** | 3.0 | 3.8 | 3.5 | **-21% discount** |
| **P/FCF** | 123x | 60x | 50x | **+105% premium** âš ï¸ |

---

### B. Relative Valuation (vs Peers)

| Company | P/E | EV/EBITDA | ROCE (%) | 3Y Growth | Comment |
|---------|-----|-----------|----------|-----------|---------|
| **Dr. Reddy's** | 18.4 | 12.2 | 22.7 | 15% | **Reasonable valuation** |
| **Sun Pharma** | 37.9 | 20-22 | 18-20 | 8-10% | Expensive |
| **Cipla** | 22.5 | 14-16 | 16-18 | 12% | Fair |
| **Lupin** | 30.4 | 16-18 | 24-25 | 12% | Expensive |
| **Aurobindo** | 18-20 | 10-12 | 18-20 | 8% | **Peer to Dr. Reddy's** |

---

### C. Intrinsic Value Estimate (DCF)

**Method:** Free Cash Flow to Firm (FCFF) discounted at WACC

**Assumptions:**
- Base Case Revenue Growth: 10-12% (FY26-30)
- EBITDA Margin: 25% (normalized)
- Terminal Growth: 6%
- Discount Rate: 13%

**Intrinsic Value Range:** â‚¹1,500 â€“ â‚¹1,750

**Bear Case:** â‚¹1,400-1,500
**Base Case:** â‚¹1,600-1,650
**Bull Case:** â‚¹1,750-1,900

---

### D. Valuation Verdict

| Zone | Price Range | Current Status | Margin of Safety |
|------|-------------|----------------|------------------|
| **Attractive (> 25% MoS)** | â‚¹1,000 â€“ â‚¹1,200 | | -4% to -8% |
| **Fair Value** | â‚¹1,200 â€“ â‚¹1,400 | âœ… **CURRENT** | 0% to +11% |
| **Overvalued** | > â‚¹1,700 | | +36%+ |

**Current Assessment at â‚¹1,250:**
- Trading at fair value to slight discount
- 10-15% upside to base case (â‚¹1,400-1,500)
- 32-40% upside to bull case with semaglutide success (â‚¹1,650-1,750)

---

## SECTION 6: TECHNICAL ANALYSIS

### A. Trend Analysis

| Timeframe | Trend | Key Levels | Comment |
|-----------|-------|------------|---------|
| **Long-term (200 DMA)** | Sideways | Support: â‚¹1,180 / Resistance: â‚¹1,350 | Below 200 DMA (~â‚¹1,280) |
| **Medium-term (50 DMA)** | Sideways | Support: â‚¹1,220 / Resistance: â‚¹1,300 | 50 DMA ~â‚¹1,267 |
| **Short-term (20 DMA)** | Consolidation | Support: â‚¹1,235 / Resistance: â‚¹1,280 | Narrow range-bound |

**52-Week Range:** â‚¹1,020 (April 2025) to â‚¹1,405 (June 2025)

---

### B. Key Technical Indicators

| Indicator | Value | Signal |
|-----------|-------|--------|
| **RSI (14)** | 48-52 | Neutral |
| **MACD** | +3.14 | Weak Buy |
| **Volume** | Below average | Caution |
| **Distance from 52W High** | -11% | Neutral |
| **Distance from 52W Low** | +22.5% | Neutral |

---

### C. Technical Verdict

**Trend Alignment:** **NEUTRAL** for accumulation

**Suggested Entry Zones:**
- **Primary Entry:** â‚¹1,180 â€“ â‚¹1,220
- **Aggressive Entry:** â‚¹1,240 â€“ â‚¹1,260 (current levels)
- **Breakout Entry:** Above â‚¹1,320 with volume

**Stop-Loss Level:** â‚¹1,150

---

## SECTION 7: RISK ANALYSIS

| Risk Category | Specific Risks | Severity |
|---------------|----------------|----------|
| **Business/Competitive** | Lenalidomide exclusivity ended (Jan 2026): -â‚¹800-1,000 Cr impact; US generic pricing erosion | **HIGH** |
| **Regulatory** | â‚¹2,396 Cr tax demand; Form 483s; PAAL for rituximab; CRL for denosumab | **HIGH** |
| **Financial** | Low FCF conversion (15%); High working capital (CCC 264 days) | **MEDIUM** |
| **Governance** | Low promoter holding (26.64%); Related party transactions | **MEDIUM** |
| **Valuation** | P/FCF 123x (very high) | **MEDIUM** |
| **Macro** | US FDA regulatory tightening; Russia-Ukraine risks; USD/INR volatility | **MEDIUM** |

### Key Monitorables:

1. **US Generics Revenue Trend:** Stabilizing post-Lenalidomide?
2. **India IPM Rank:** Continuing march to Top 5?
3. **Semaglutide Launch:** Canada (Feb-May 2026), India (Mar 21, 2026)
4. **Biosimilar Approvals:** Rituximab, Abatacept, Denosumab
5. **Tax Litigation:** Settlement or escalation?
6. **FCF Conversion:** Improving above 50%?

---

## SECTION 8: INVESTMENT THESIS

### Bull Case (â‚¹1,650-1,750 | 32-40% Upside)

**What Goes Right:**

1. **Semaglutide Dominance:**
   - Day 1 launch in India (Mar 21, 2026) and Canada
   - Captures 15-20% market share
   - Total semaglutide revenue: â‚¹1,000-1,200 Cr by FY28

2. **Biosimilar Wins:**
   - Rituximab (US) approved by H2 FY26
   - Abatacept (US/EU) approved FY27
   - Combined â‚¹1,000-1,500 Cr peak sales

3. **India Franchise Acceleration:**
   - Maintain 15-18% growth
   - IPM rank improves to #7-8

4. **US Generics Stabilization:**
   - Complex generics pipeline
   - Base business erosion limited to 3-5%

5. **Margin Expansion:**
   - Capex cycle ends â†’ FCF improves
   - EBITDA margin 26-27%

**Probability:** 30%

---

### Base Case (â‚¹1,450-1,550 | 16-24% Upside)

**Most Likely Scenario:**

1. **Semaglutide Moderate Success:**
   - India market share 8-10%
   - Total: â‚¹500-600 Cr by FY28

2. **Biosimilars Delayed but Eventually Approved:**
   - Rituximab delayed to FY27
   - Abatacept on track

3. **India Solid, US Slow Recovery:**
   - India: 14-16% growth
   - US: Stabilizes at current levels

4. **Margins Normalize:**
   - EBITDA margin 24-25%
   - FCF conversion improves to 50-60%

5. **Tax Case Settlement:**
   - Negotiated at â‚¹800-1,000 Cr

**Probability:** 50%

---

### Bear Case (â‚¹1,050-1,150 | 16-8% Downside)

**What Goes Wrong:**

1. **Semaglutide Flop:**
   - Canada approval delayed to 2027
   - 15+ players flood market
   - Contribution: <â‚¹200 Cr by FY28

2. **Biosimilar Rejections:**
   - Rituximab receives CRL
   - 2-3 year delays

3. **Regulatory Crisis:**
   - USFDA warning letter
   - Tax case adverse outcome

4. **US Generics Collapse:**
   - Competition intensifies
   - US revenue declines 10-12%

5. **Margin Compression:**
   - EBITDA margin 22-23%

**Probability:** 20%

---

## SECTION 9: FINAL RECOMMENDATION

### Scorecard

| Parameter | Assessment |
|-----------|------------|
| **Moat Quality** | **NARROW** |
| **Financial Strength** | **STRONG** |
| **Management Quality** | **MEDIUM** |
| **Valuation** | **FAIR VALUE** |
| **Technical Setup** | **NEUTRAL** |

---

### **RECOMMENDATION: BUY (with Caution)** â­â­â­/5

**Rationale:**

**âœ… Positives:**
1. Semaglutide optionality (â‚¹1,000-1,500 Cr potential)
2. Valuation: 15-20% discount to sector
3. Balance Sheet: Net cash, conservative leverage
4. India Franchise: Strong momentum (19% growth, #9 IPM)
5. Biosimilar Pipeline: â‚¹1,000-1,500 Cr peak sales potential

**âŒ Concerns:**
1. Regulatory Overhang: Form 483s, PAAL, CRL, â‚¹2,396 Cr tax notice
2. US Generics Headwinds: Lenalidomide cliff, pricing erosion
3. Low FCF Conversion: 15% is worrisome
4. Governance: Related party transactions, low promoter holding
5. Competition: Semaglutide crowded; biosimilars face giants

---

### Action Plan: BUY with Staged Entry

**Position Sizing:** 3-5% of portfolio

**Accumulation Strategy:**

**Phase 1 (Immediate):** 40% of planned position
- **Entry:** â‚¹1,180 â€“ â‚¹1,240
- **Action:** Start accumulating on dips

**Phase 2 (Mar-Apr 2026):** 30% of planned position
- **Trigger:** Semaglutide India launch success + Canada approval
- **Entry:** â‚¹1,200 â€“ â‚¹1,280

**Phase 3 (Q1FY27 - Jul-Aug 2026):** 30% of planned position
- **Trigger:** Q4FY26 results show India growth >15%, US stabilizing
- **Entry:** â‚¹1,150 â€“ â‚¹1,300

---

### Price Targets

| Scenario | Target | Timeframe | Upside/Downside from â‚¹1,250 |
|----------|--------|-----------|------------------|
| **Bear** | â‚¹1,050 â€“ â‚¹1,150 | 12-18M | -16% to -8% |
| **Base** | â‚¹1,450 â€“ â‚¹1,550 | 12-18M | +16% to +24% |
| **Bull** | â‚¹1,650 â€“ â‚¹1,750 | 18-24M | +32% to +40% |

**Probability-Weighted Target:** â‚¹1,420 (+13.6%)

---

### Review Triggers

**Buy More If:**
1. Price dips to â‚¹1,150-1,180 AND fundamentals intact
2. Semaglutide India launch captures >10% market share
3. Rituximab US approval announced
4. Tax case settled <â‚¹1,000 Cr

**Hold If:**
1. Price â‚¹1,200-1,350 AND gradual progress
2. US generics declining <5% annually
3. India growth >14%

**Sell If:**
1. Tax case adverse outcome >â‚¹1,500 Cr
2. USFDA warning letter for key facility
3. Semaglutide launch delayed beyond Q2 FY27
4. US generics revenue declines >15% in any quarter
5. Price rallies above â‚¹1,600 before revenues materialize

---

## SECTION 10: QUICK REFERENCE CARD

```
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
COMPANY: Dr. Reddy's Laboratories Ltd
SECTOR: Pharmaceuticals
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
MOAT: NARROW (Regulatory, Scale)
ROCE (5Y): 20.4% âœ…
DEBT/EQUITY: 0.16 âœ… (Net Cash â‚¹3,069 Cr)
FCF YIELD: 0.8% âš ï¸ (Low due to high capex cycle)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
P/E (Current vs 10Y Median): 18.4x vs 21.0x (-12% discount)
EV/EBITDA: 12.2x (attractive)
P/FCF: 123x (elevated - red flag)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
INTRINSIC VALUE: â‚¹1,500 - â‚¹1,750
CMP: â‚¹1,250
MARGIN OF SAFETY: +20% to +40%
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
RECOMMENDATION: BUY â­â­â­/5
ENTRY ZONE: â‚¹1,180 - â‚¹1,260 (Staged)
STOP LOSS: â‚¹1,150 (Technical + Fundamental)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
TARGET (Base): â‚¹1,450-1,550 (16-24% upside, 12-18M)
TARGET (Bull): â‚¹1,650-1,750 (32-40% upside, 18-24M)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
KEY RISK: â‚¹2,396 Cr tax notice + Regulatory issues
KEY CATALYST: Semaglutide launch (Mar 2026 India,
              Feb-May 2026 Canada) + Biosimilar approvals
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
POSITION SIZE: 3-5% of portfolio (Satellite holding)
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## FINAL VERDICT

Dr. Reddy's is a **quality pharma compounder trading at fair value** with significant upside optionality from semaglutide and biosimilars. However, multiple regulatory/governance headwinds and low FCF conversion prevent this from being a "Strong Buy."

**Best for:** Investors seeking:
- 15-20% annual returns over 18-24 months
- Exposure to India pharma theme
- GLP-1/biosimilar optionality
- Willing to tolerate regulatory/governance risks

**Not suitable for:** Conservative investors seeking:
- Consistent FCF generation
- Bullet-proof governance
- Dividend income (0.65% yield)

**Next Steps:**
1. Start nibbling at â‚¹1,220-1,240
2. Watch March 21, 2026 semaglutide India launch closely
3. Monitor Canada approval timeline (Feb-May 2026)
4. Reassess post-Q4FY26 results (May 2026)

**Long-term (3-5 years):** If semaglutide and 2-3 biosimilars succeed, Dr. Reddy's can compound at 15-18% CAGR with stock potentially reaching â‚¹2,000-2,200 by 2029-30. But the path will be volatile.

---

**Disclaimer:** This analysis is for educational purposes only. Conduct your own due diligence and consult a financial advisor before investing.

---

**Analysis Completed:** February 6, 2026
**Next Review:** Post Q4 FY26 Results (Expected: May 2026)
